Mdma molecule:

Image from PubChem

Mdma Clinical Trials


The Effect of 3, 4-Methylenedioxymethamphetamine (MDMA)-assisted therapy on Mood and Anxiety symptoms in advanced-stage Cancer Study


To see complete record on anzctr.org.au, please visit this link

Id: ACTRN12619001334190p

Organisation Name: University of Otago

Overal Status: Not yet recruiting

Start Date: 01/06/2020

Brief Summary: EMMAC is a randomised controlled trial studying the effects of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer patients. Standard dose MDMA (120mg + optional 60mg) will be compared to a psychoactive placebo (Methylphenidate 20mg + optional 10mg) with both being given as a single dose. On the basis of MDMA pharmacology and recent research showing promising results with the use of psilocybin to reduce anxiety and depression in patients with advanced-stage cancer (Grob et al., 2011, Griffiths et al., 2016, Ross et al., 2016) we hypothesise that MDMA may have the potential to achieve similar positive mental health outcomes with reduced psychological risk given the differences in psychopharmacological effects.

Countries:
  • New Zealand
Conditions:
  • Depression symptoms
  • Anxiety symptoms
  • Advanced-stage cancer


Total execution time in seconds: 0.087417125701904